The cancer chemopreventive potential of sarcophine-diol in a chemical carcinogen initiation-promotion experimental tumor model in mice was evaluated. Sarcophine-diol, when given orally, afforded significant protection in the mouse skin cancer model initiated by the topical administration of (±)-(E)-4-methyl-2-[(E)-hydroxyamino]-5-nitro-6-methoxy-3-hexanamide (NOR-1) and promoted by 12-O-tetradecanoylphorbol-13-acetate (TPA). These findings, along with our initial reports, suggest that sarcophine-diol is an effective cancer chemopreventive agent, even when administered orally and at a very low dose and thus indicating possible potential human applications in the control of malignancy.
Cancer is the second most common cause of mortality, exceeded only by heart disease [1] , and the failure of conventional chemotherapy to reduce its mortality indicates that new approaches are critically needed. There is growing interest in marine natural products for preventing [2] or inhibiting cancer development [3] [4] [5] . Our laboratory has explored the skin cancer chemopreventive effects of sarcophine-diol, a semi-synthetic derivative of sarcophine, a cembranolide isolated from the Red Sea coral Sarcophyton glaucum [6a-6i] .
Our previous studies showed the potential of sarcophine-diol as a chemopreventive agent using Epstein-Barr virus early antigen activation induced by the tumor promoter 12-Otetradecanoylphorbol-13-acetate (TPA) as an index of tumor promoting potential [6a,d] . We also demonstrated that sarcophinediol treatment inhibits skin tumor development in UV-induced skin cancer in SKH-1 hairless mice [6f] . Our subsequent studies demonstrated that sarcophine-diol decreases cell viability in human epidermoid carcinoma A431 cell line in a concentration-dependent manner [6h]. Recent results also showed the inhibition of the expression levels of several biomarkers of proliferation and apoptosis [6i] . Based on this strong cancer chemopreventive activity of sarcophine-diol, we extended our studies to determine further the cancer chemopreventive potentials of the compound in a different in vivo, long-term tumor model for possible human applications. The present study evaluated the cancer chemopreventive effect of oral sarcophine-diol at a low dose of 0.0025% (2.5 mg/100 mL water) in mice to evaluate the chemoprevention effect of NOR-1-induced TPA-promoted skin carcinogenesis.
Sarcophine-diol inhibits carcinogenesis in the NOR-1 initiated TPA-promoted two-stage mouse skin carcinogenesis model. The O OH OH Sarcophine-diol procedure followed for this assay was essentially that as reported [7a] .Tumor development was induced by (±)-(E)-4-methyl-2-[(E)-hydroxyamino]-5-nitro-6-methoxy-3-hexanamide (NOR-1) and promoted by 12-O-tetradecanoylphorbol-13-acetate. The protocol involved treatment of female hairless HOS: HR-1 mice. One week prior to initiation, the test animal group was given 0.0025% sarcophine-diol (2.5 mg/100 mL) in drinking water, whereas the control group received only drinking water. On the day of tumor initiation, the back of each mouse was treated topically with a single dose of NOR-1 (390 nmol) in 0.1 mL of pH 10 alkaline solution. One week after initiation, oral feeding of sarcophine-diol to the test group was stopped and replaced by oral feeding of drinking water and the animals in each group were treated with TPA (1.7 nmol in 0.1 ml of acetone) for 20 weeks. Two treatment groups were studied as follows: group 1, NOR-1 + TPA and group 2, NOR-1 + TPA + 0.0025% sarcophine-diol. The animals were examined weekly. Animal survival, mean latency period of tumor formation and gross tumor incidence were recorded. Sarcophine-diol delays the incidence and decreases the number of tumors in the NOR-1 initiated TPA-promoted two-stage mouse skin carcinogenesis model. In the NOR-1-TPA treated group, the induced skin tumors appeared as early as the 7th week after the TPA promotion. Oral administration of as low as 0.0025% of sarcophine-diol in drinking water 1-week prior to and after the tumor initiation resulted in the delay of the tumor induction in the animals with the first tumor appearing after a 2 week delay. The average number of papillomas or tumors per mouse in the sarcophine-diol-treated groups was significantly lower (P < 0.05, Student's t-test) than those of the non-sarcophine-diol-treated groups at 20 weeks of tumor promotion (Figure 1a) . For example, after 20 weeks, the number of tumors per mouse in the test group was 3 compared with 7 in the untreated controls (58% reduction). In addition, sarcophine-diol showed a significant inhibition of the multiplicity of papillomas. For example, after 13 weeks, sarcophine-diol treatment showed about 60% inhibition of the number of papillomas formed per mouse when compared with the non-treated controls (Figure 1b ). There were no differences in the weight profiles between the two groups. This study demonstrates the efficacy of sarcophine-diol for long term suppression of skin tumors induced by different chemical carcinogens in mice and is compatible with our previous studies [6], indicating that administration of sarcophine-diol has cancer chemopreventive potential.
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Experimental

Animals:
Female HOS: HR-1 strain specific, pathogen-free, 6 week old, hairless mice were purchased from Hoshino Animal Factory, Saitama, Japan, and the female ICR specific, pathogen free mice from Japan SLC (Skizuoka), Japan. The animals were housed (5 animals per cage) in a temperature, humidity and dark/light controlled colony. The animals were fed ad libitum with a standard laboratory diet and water.
Semi-synthesis of sarcophine-diol (SD): Sarcophine was isolated from Sarcophyton glaucum following the reported procedure [7b]. Sarcophine-diol was synthesized from sarcophine using a two-step reaction according to our published procedures [6b].
Anticarcinogenecity studies: The cancer chemopreventive effect of sarcophine-diol was evaluated following the reported procedure for the NOPR-1-TPA two-stage mouse skin carcinogenesis model [7a] .
Tumor formation was induced with NOR-1 and promoted with TPA. One week prior to initiation, the test animal group was given 0.0025% sarcophine-diol (2.5 mg/100 mL) in drinking water, whereas the control group received only drinking water. On the day of tumor initiation, the back of each mouse was treated topically with a single dose of NOR-1 (390 nmol) in 0.1 mL pH 10 alkaline solution. One week after initiation, oral feeding of sarcophine-diol to the test group was stopped and replaced by oral feeding of drinking water and the animals in each group were treated with TPA (1.7 nmol in 0.1 mL of acetone) for 20 weeks. Two treatment groups were studied as follows: group 1 (test): NOR-1+TPA; group 2 (untreated control): NOR-1+TPA + 0.0025 % sarcophine-diol. The animals were examined weekly. Animal survival, mean latency period of tumor formation and gross tumor incidence were recorded.
Data evaluation:
The effect of sarcophine-diol on experimental carcinogenesis was evaluated by comparing the observed results (NOR-1-TPA) with the control group. Statistical analyses of all these data used ANOVA, X 2, and Student's t test on sample means using INSTAT software (Graph Pad, San Diego, CA). X 2 was used for analyzing the data in tumor incidence. ANOVA and student's t test were used for the data analysis in tumor multiplicity.
Significance was considered at P < 0.05.
